Meningococcal group B vaccine - Pfizer

Drug Profile

Meningococcal group B vaccine - Pfizer

Alternative Names: Bivalent recombinant LP2086; Bivalent recombinant meningococcal B vaccine - Pfizer; Bivalent rLP2086; Meningococcal B rLP2086 vaccine - Pfizer; MnB-rLP2086; PF-05212366; PF-5212366; Recombinant-LP2086; rLp-2086; rLP2086; TRUMENBA

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 23 Apr 2018 Meningococcal group B vaccine - Pfizer receives Breakthrough Therapy status for Meningococcal group B infections (In infants, In children) in USA
  • 06 Mar 2018 Launched for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in Canada (IM)
  • 01 Jan 2018 Pfizer completes a phase III trial for Meningococcal group B infections (In adolescents, In children, Prevention, In adults) in USA, Czech Republic, Denmark, Finland, Germany, Sweden, and Poland (IM) (NCT01543087) (EudraCT2011-005697-31)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top